Abstract 5093
Background
PDR (Pulsed Dose Rate) Brachytherapy is one of the treatments of choice for cervical cancer. Main side-effects are vaginal dryness, dyspareunia, pain, stenosis and sexual dysfunction that impacts on the patient’s well-being and on quality of life. To evaluate the efficacy of vaginal moisture to reduce dryness and pain associated with PDR Brachytherapy in cervical cancer patients treated at Catalan Institute of Oncology-Barcelona.
Methods
A quasi-experimental randomized study. From 2016 to 2018 all women were assessed by nurses 4 times: basal at discharge, 1st, 3rd and 6th month post-treatment. Experimental intervention with moisturizing versus standard care. Inclusion criteria; women diagnosed of cervical cancer receiving PDR. Probabilistic sampling of patients assigned 42 to control group CG and 47 to experimental group (EG). Variables: vaginal hydration, pain, age, ethnicity, comfort perceived, socio-demographic, tobacco, sexual relationship and couples. Instruments: LENT/SOMA to assess vaginal toxicity and visual numeric for pain.
Results
Of the 96 eligible, some excluded for relapse, or study failure. N = 89 women. Mean age: 52.78 + 12.8 (range 24-83) years old. Ethnicity; 63.8% white, Latina 3.1%, Arabic and Asiatic 0.8% each and gypsies 1.6%. Education; 3.1% illiteracy, primary 32.2%, secondary 25.2% and university 7.2%. Smokers 29.2%. For variable pain was 15-15-17-15 in CG and 20-17-15-13 in EG for consecutive points. Dyspareunia was present in 0-4-8-7 patients and 3-0-2-2 in EG. Dryness was 1-9-13-12 in CG and 6-1-8-10 in EG. Bleeding was 17-5-5-7 in CG and 16-10-0-6 in EG. Only significance differences on dryness variable. A total of 48.31% women avoid sexual intercourse, 22 (24.71%) in CG and 21 (23.59%). No significance differences.
Conclusions
An early vaginal moisturizing post-brachytherapy decreases the appearance of dyspareunia, allows start sexual relationships and improves the quality of life and sense of well-being. However some patients do not give the necessary importance to sexuality and it is something that they put aside during the treatment. Nursing education for patients at discharge helps to facilitate a healthy sexuality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract